Please ensure Javascript is enabled for purposes of website accessibility

Why Voyager Therapeutics Stock Is Sinking Today

By George Budwell – Oct 13, 2020 at 9:10AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A clinical hold is weighing on the biotech's shares today.

What happened

Shares of the clinical-stage gene therapy company Voyager Therapeutics (VYGR -0.54%) dropped by as much as 11% in pre-market trading Tuesday morning. The biotech's shares are responding negatively to a regulatory delay for its Huntington's disease candidate, VY-HTT01.

After market close yesterday, Voyager announced that the Food and Drug Administration placed a clinical hold on the experimental gene therapy pending the resolution of certain chemistry, manufacturing, and controls (CMC) matters. The company said it expects to receive further details about the hold from the FDA within 30 days.  

Close up image of a double helix.

Image source: Getty Images.

So what

Huntington's disease is a genetic neurological condition that results in the death of cells within the brain. At present, there are an estimated 30,000 to 40,000 individuals within the U.S. who have this deadly neurological disorder, according to the peer-reviewed research. Moreover, there are no FDA approved drugs or therapies that treat the underlying cause of the disease.

Voyager is thus targeting a rather sizable commercial opportunity with VY-HTT01. This gene therapy will more than likely be a blockbuster product -- with sales of over $1 billion per year -- if it gains market access. Viewed in this light, it's easy to understand why investors aren't too happy about this clinical hold. 

Now what

A clinical hold for CMC matters isn't the end of the world. Far from it. The long and short of it is that VY-HTT01's clinical program should get back on track in the not-so-distant future, perhaps before the end of the year. 

George Budwell has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Voyager Therapeutics Stock Quote
Voyager Therapeutics
VYGR
$5.54 (-0.54%) $0.03

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
349%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.